Ozempic Side Effects: Frequency Data, Clinical Risk, and How to Manage Them

The SmPC lists gastrointestinal adverse reactions as the most frequently reported side effects of Ozempic (semaglutide 0.25 mg, 0.5 mg, and 1 mg subcutaneous injection).

These reactions are dose-dependent and peak during the titration phase.

Reported frequencies from the SUSTAIN clinical programme:

• Nausea: very common (affects more than 1 in 10 patients), reported in approximately 20% of trial participants at the 1 mg dose
• Diarrhoea: common (1 in 10 to 1 in 100), occurring in roughly 9% of patients
• Vomiting: common, more pronounced during the first 4 weeks of each dose step
• Constipation: common, affecting around 5% of patients across all dose groups
• Abdominal pain and bloating: common, typically mild to moderate in severity

These effects result from semaglutide's action on gastric emptying. The drug slows gastric motility, which contributes to appetite suppression but also produces the GI symptoms described above.

Following the recommended dose titration schedule (starting at 0.25 mg weekly for 4 weeks, then 0.5 mg) significantly reduces the incidence and severity of these reactions.

Most patients report meaningful improvement after 4 to 8 weeks at a stable dose.

Beyond the gastrointestinal cluster, several less common adverse effects appear in the SmPC at frequencies between uncommon (1 in 100 to 1 in 1,000) and common.

• Injection site reactions: erythema, pruritus, and induration at the injection site occur in approximately 0.6% of patients
• Dizziness and headache: reported at common frequency, often linked to shifts in blood glucose rather than a direct CNS effect of the drug
• Fatigue: not prominently listed in the SmPC but widely reported in post-marketing surveillance and patient forums. Caloric restriction from appetite suppression is the likely driver
• Dysgeusia (altered taste): uncommon. Some patients describe a metallic or dull taste that resolves spontaneously
• Raised lipase and amylase: elevations of pancreatic enzymes occur in a proportion of patients without clinical pancreatitis. NICE CG 181 advises monitoring if symptoms develop, not routine enzyme screening
• Alopecia: reported at low frequency. Rapid weight loss rather than semaglutide itself is considered the probable cause, consistent with telogen effluvium

These reactions rarely require treatment discontinuation. If injection site reactions recur at the same location, rotating the injection site (abdomen, thigh, upper arm) usually resolves the problem.

Acute pancreatitis is listed as an uncommon adverse reaction in the semaglutide SmPC. The BNF flags it under cautions for all GLP-1 receptor agonists.

Pancreatitis:

Patients should be advised to seek urgent medical attention if they develop severe, persistent abdominal pain radiating to the back, accompanied by nausea and vomiting.

In SUSTAIN trials, the incidence was approximately 0.1 to 0.2% across all dose groups. Ozempic must be permanently discontinued if pancreatitis is confirmed.

The BNF contraindicates re-challenge with any GLP-1 receptor agonist after a confirmed episode.

Cholelithiasis (gallstones):

Rapid weight loss increases bile lithogenicity. In the STEP trials of higher-dose semaglutide (2.4 mg, marketed as Wegovy), cholelithiasis was reported in 1.6% of the semaglutide group versus 0.

7% of the placebo group. Patients who lose more than 1.5 kg per week may benefit from dietary fat intake advice to maintain gallbladder motility.

Thyroid C-cell tumours:

Semaglutide carries a boxed warning in the US prescribing information based on rodent thyroid C-cell tumour findings at high doses.

The MHRA SmPC does not carry an equivalent warning, but the drug remains contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2.

Ozempic as monotherapy carries a low risk of hypoglycaemia because semaglutide's insulin secretion is glucose-dependent. The SmPC categorises hypoglycaemia as uncommon when Ozempic is used alone.

The risk increases substantially when Ozempic is combined with sulfonylureas or insulin.

NICE NG 28 recommends reviewing the sulfonylurea or insulin dose when adding a GLP-1 receptor agonist, typically reducing the sulfonylurea dose by 50% at initiation.

Clinical signs of hypoglycaemia to communicate to patients:

• Tremor, sweating, pallor, and palpitations (adrenergic symptoms, onset within minutes)
• Confusion, difficulty concentrating, and visual disturbance (neuroglycopaenic symptoms)
• Blood glucose below 4.0 mmol/L on capillary testing

Practical management:

• Patients on combination therapy should carry rapid-acting glucose (e.g. dextrose tablets or 150 ml fruit juice)
• HbA1c reductions with Ozempic typically range from 10 to 18 mmol/mol (1.0 to 1.8%) depending on baseline, which may necessitate insulin dose adjustments
• Self-monitoring frequency should increase during the titration phase, particularly in the first 4 weeks after each dose step

Patients using Ozempic for weight management without concomitant diabetes medications have minimal hypoglycaemia risk.

Most Ozempic side effects respond to straightforward lifestyle adjustments. The following strategies align with BNF and NICE guidance on GLP-1 receptor agonist management.

For nausea and vomiting:

• Eat smaller, more frequent meals. Three large meals per day worsen delayed gastric emptying symptoms
• Avoid high-fat, greasy, or heavily spiced foods during the titration phase
• Eat slowly and stop before feeling full. Semaglutide changes satiety signalling, and overeating is the most common trigger for nausea
• Stay upright for at least 30 minutes after eating

For constipation:

• Increase dietary fibre gradually (aim for 25 to 30 g per day)
• Maintain fluid intake of at least 1.5 to 2 litres daily
• Regular physical activity (even 20 minutes of brisk walking) promotes colonic motility

For fatigue:

• Ensure adequate protein intake (at least 1.2 g per kg body weight daily) to preserve lean mass
• Check ferritin, B12, and folate levels if fatigue persists beyond 8 weeks
• Maintain consistent sleep hygiene

General principles:

• Follow the dose titration schedule without skipping steps
• Inject at the same time each week to maintain steady plasma levels
• Keep a symptom diary and bring it to clinic reviews for dose adjustment discussions

Most Ozempic side effects are self-limiting and manageable at home. Certain presentations, however, require prompt medical assessment.

Attend A&E or call 999 if you experience:

• Severe, unrelenting abdominal pain lasting more than 2 hours, particularly with vomiting (possible pancreatitis)
• Signs of anaphylaxis: swelling of the face, lips, or throat, difficulty breathing, widespread urticaria. This is very rare but documented in the SmPC
• Symptoms of severe dehydration from prolonged vomiting or diarrhoea: reduced urine output, postural dizziness, confusion

Contact your GP or diabetes specialist nurse if:

• Nausea or vomiting persists beyond 2 weeks at the same dose and interferes with daily function
• You notice persistent right upper quadrant pain (possible gallstone disease)
• Blood glucose readings fall below 4.0 mmol/L on more than two occasions in a week
• You develop visual changes. Rapid HbA1c improvement can temporarily worsen diabetic retinopathy. NICE NG 28 recommends more frequent retinal screening during the first year of intensified glycaemic control
• Weight loss exceeds 1 kg per week consistently, increasing gallstone risk

Your prescriber can adjust your dose, extend the titration schedule, or switch therapy if side effects remain unacceptable after 8 to 12 weeks.